重磅!恒瑞医药口服小分子GLP-1RA(HRS-7535)糖尿病肾病最新研究亮相ASN 2025

恒瑞医药
Nov 13, 2025

糖尿病肾病(DKD)是2型糖尿病(T2DM)最常见的微血管并发症,也是全球终末期肾病(ESKD)的首要致病因素。当前,尽管已有肾素-血管紧张素系统抑制剂(RASi)、钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)等作为DKD标准治疗方案中的推荐药物,但仍有大量已接受标准治疗的DKD患者面临蛋白尿进展与肾功能下降的高残留风险,临床对更有效治疗手段的需求极为迫切。GLP-1受体激动剂(GLP-1RA)虽...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10